@Article{Farsang2009,
journal="Archives of Medical Science Special Issues",
issn="1734-1922",
year="2009",
title="Invited reviewCannabinoids and cardiometabolic risk",
abstract="The regulatory role of the endocannabinoid system has been implicated in many physiological and pathological functions and as a consequence the modulation of function of this system has become a therapeutic target in various diseases and pathological states. The authors give an overview of the pharmacological background of the endocannabinoid system and a short summary of the most important preclinical data. The connection between the endocannabinoid system and cardiometabolic risk is also discussed. Finally, landmark human studies with the cannabinoid antagonist rimonabant \– such as the RIO, SERENADE, ARPEGGIO, STRADIVARIUS and ADAGIO-LIPIDS studies \– are also reviewed.",
author="Farsang, Csaba
and Járai, Zoltán",
pages="281--281",
url="https://www.termedia.pl/Invited-review-Cannabinoids-and-cardiometabolic-risk,52,12937,1,1.html"
}